SCHEMBL9986299

SCHEMBL9986299

O=C1CC2(CCN1)CCC1(CCCOC1)CC2

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23119744 0.82 GAA (0.41) GAA
SCHEMBL20758911 0.80 GAA (0.40) GAA
SCHEMBL6560160 0.80 OR51E2 (0.39) GAA
SCHEMBL16190024 0.80
SCHEMBL9986841 0.78 OR51E2 (0.34) GAA
SCHEMBL23119745 0.78 GAA (0.48) GAA
SCHEMBL20633689 0.78 OR51E2 (0.37) GAA
SCHEMBL16503412 0.73
SCHEMBL503340 0.72 ALDH1A1 (0.33) GAA
SCHEMBL1133336 0.72 NEK2 (0.39) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585444-A1 AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS Boehringer Ingelheim International GmbH (DE) 2013-05-01 EP disclosed
WO-2011161128-A1 AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-29 WO disclosed